300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Africa
Poland
Oman
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Shinsei Capital Partners, VC Fund

Shinsei Capital Partners

VC Fund

Tokyo, Japan

Shinsei Capital Partners is a VC fund in Tokyo focused on Health Care and Pharmaceutical. Shinsei Capital Partners invested startup companies engaged in life science such as biotech or digital health technology.

Total investments:
9
Last investment:
Lead investor:
11%
Fund size:
$92M
Last fund:

Last updated:

Industries Shinsei Capital Partners invests in

Health CarePharmaceuticalSNSAndroidContent

Stages Shinsei Capital Partners invests in

Series BSeedSeries AFunding RoundVenture - Series Unknown

Countries Shinsei Capital Partners invests in

Japan

Round sizes

Seed $2.2M–$5MSeries B $2.3M–$27M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$2.2M–$5M
Series B
$2.3M–$27M

Investment Focus

Industry

  • Health Care 2 (22%)
  • Pharmaceutical 2 (22%)
  • SNS 1 (11%)
  • Android 1 (11%)
  • Content 1 (11%)
See all 20 industries →

Stage

  • Series B 4 (44%)
  • Seed 2 (22%)
  • Series A 1 (11%)
  • Funding Round 1 (11%)
  • Venture - Series Unknown 1 (11%)

Team

NameTitleInvestmentsLinksEmail
Manabu Nakamura
Manabu Nakamura Founder, CEO and Managing Partner
Founder, CEO and Managing Partner Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
MiddleField is a team to make cars the best entertainment and to make the lives of everyone involved in cars into entertainment. They creates a society where a lot of people are involved as a middle point of all people's dreams. MiddleField owns and operates an e-commerce platform offering cars. $2.3M / Series B / Oct 13, 2020
FunPep is an Industry-university collaboration bioventure company. $14.1M / Venture - Series Unknown / Aug 14, 2020
Financier provides Japan's only Web3 platform aimed at realizing a creator economy that supports the challenges of 1 billion people. The platform enables creators to issue tokens, fostering community engagement and new economic models. By leveraging blockchain technology, it empowers individuals to monetize their influence and buildsustainable communities. $2.2M / Seed / Apr 30, 2020
Mira Robotics is a software based company provide services that can robots in various fields. $5M / Seed / Jan 15, 2020
Through the development of next-generation multifunctional biopharmaceuticals (neobiologics) using technology based on a unique new concept , we will realize our mission, grow as a global company, and contribute to human health care. By developing biopharmaceuticals with new modalities using LassoGraft Technology ® as a core technology, we willwork on solving unmet medical needs, satisfying treatment methods in the field of rare diseases, and proposing solutions to expensive medical problems. $77.8M / Jan 15, 2020
Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo. $25M / Series B / Apr 10, 2019
AlphaNavi Pharma specializes in the research and development of new drugs. $8.1M / Series A / Apr 05, 2019
Chordia Therapeutics is a research and development type bioventure specializing in oncology field. The company has a mission of delivering new therapeutic drugs to patients as soon as possible in the area of ​​cancer with high unmet medical need. $26.9M / Series B / Apr 01, 2019
Veritas In Silico is a start-up to research and sales of pharmaceuticals.Veritas In Silico, target partial structures in messenger RNA (mRNA) by exploring the true form of RNA, the origin of life, based on in silico (computer-based computational science) technology Established a drug discovery system with a completely new concept.This mRNA-targeteddrug has the potential to be applied to any disease, including those for which it has been difficult to develop therapeutic drugs using conventional protein-based drug discovery. Therefore, it is expected to be a favorite for next-generation drug discovery that will cause a paradigm shift in the pharmaceutical industry. $7.2M / Series B / Mar 29, 2019

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Africa
Poland
Oman
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Shinsei Capital Partners invest in?

Shinsei Capital Partners invests primarily in Health Care, Pharmaceutical and SNS startups, most often at Series B and Seed stage. Most of the 9 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Shinsei Capital Partners invest in?

Shinsei Capital Partners typically joins rounds of $2.2M–$5M at Seed and $2.3M–$27M at Series B. These are whole funding-round sizes, not Shinsei Capital Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Shinsei Capital Partners took part in.

How do I contact Shinsei Capital Partners?

Public channels for Shinsei Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Shinsei Capital Partners?

The team at Shinsei Capital Partners includes Manabu Nakamura (Founder, CEO and Managing Partner). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Shinsei Capital Partners Shinsei Capital Partners Find emails